Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Non-Current Debt (2022 - 2025)

Historic Non-Current Debt for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $50.9 million.

  • Taysha Gene Therapies' Non-Current Debt rose 1834.03% to $50.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.9 million, marking a year-over-year increase of 1834.03%. This contributed to the annual value of $43.9 million for FY2024, which is 847.73% up from last year.
  • Latest data reveals that Taysha Gene Therapies reported Non-Current Debt of $50.9 million as of Q3 2025, which was up 1834.03% from $41.1 million recorded in Q2 2025.
  • Taysha Gene Therapies' Non-Current Debt's 5-year high stood at $50.9 million during Q3 2025, with a 5-year trough of $37.4 million in Q1 2022.
  • Its 4-year average for Non-Current Debt is $40.4 million, with a median of $38.5 million in 2023.
  • Its Non-Current Debt has fluctuated over the past 5 years, first tumbled by 135.32% in 2024, then surged by 1834.03% in 2025.
  • Over the past 4 years, Taysha Gene Therapies' Non-Current Debt (Quarter) stood at $38.0 million in 2022, then grew by 6.69% to $40.5 million in 2023, then grew by 8.48% to $43.9 million in 2024, then rose by 15.73% to $50.9 million in 2025.
  • Its Non-Current Debt was $50.9 million in Q3 2025, compared to $41.1 million in Q2 2025 and $42.5 million in Q1 2025.